| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Department of Medical Oncology, Beatson Institute for Cancer Research, Glasgow, United Kingdom; and 2 Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom
Gene expression was analyzed in five pairs of 5-fluorouracil (5-FU) resistant and parental cancer cell lines on DNA microarrays. In unsupervised analysis, a prediction rule was built from the expression profiles of 29 genes, and 5-FU sensitivity class was predicted with 100% accuracy and high predictive strength. In supervised analysis of key 5-FU pathways, expression of 91 genes was associated with 5-FU sensitivity phenotype and segregated samples accordingly in hierarchical analysis. Key genes involved in 5-FU activation were significantly down-regulated (thymidine kinase, 2.9-fold; orotate phosphoribosyltransferase, 2.3-fold; uridine monophosphate kinase, 3.2-fold; pyrimidine nucleoside phosphorylase 3.6-fold) in resistant cells. Overexpression of thymidylate synthase and its adjacent gene, c-Yes, was detected in the resistant cell lines. The mRNA and protein overexpression of nuclear factor 
B (NFB) p65 and related antiapoptotic c-Flip gene was detected in resistant cells. The 5-FU-resistant cell lines also showed high NFB DNA-binding activity. Cotransfection of NFB p50 and p65 cDNA induced 5-FU resistance in MCF-7 cells. Both NFB- and 5-FU-induced resistant cell lines manifested reduced expression of genes governing G1-S and S-phase transition. Expression of genes involved in DNA replication was also down-regulated in resistant cell lines. These findings were highly consistent with the slower growth rate, higher proportion of G1, and lower proportion of S-phase cells in the resistant cell lines. This phenotype may protect resistant cells from cell death induced by incorporation of 5-FU into DNA chains, by allowing time to repair 5-FU-induced damage. Our findings may provide novel targets for tackling 5-FU resistance.
This article has been cited by other articles:
|
|
 |
|
  M. Derenzini, G. Donati, G. Mazzini, L. Montanaro, M. Vici, C. Ceccarelli, D. Santini, M. Taffurelli, and D. Trere Loss of Retinoblastoma Tumor Suppressor Protein Makes Human Breast Cancer Cells More Sensitive to Antimetabolite Exposure Clin. Cancer Res., April 1, 2008; 14(7): 2199 - 2209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. An, P. Robins, T. Lindahl, and D. E. Barnes 5-Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug Cytotoxicity Cancer Res., February 1, 2007; 67(3): 940 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Ralstin, E. A. Gage, M. T. Yip-Schneider, P. J. Klein, E. A. Wiebke, and C. M. Schmidt Parthenolide Cooperates with NS398 to Inhibit Growth of Human Hepatocellular Carcinoma Cells through Effects on Apoptosis and G0-G1 Cell Cycle Arrest Mol. Cancer Res., June 1, 2006; 4(6): 387 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Petty, K. M. Kerr, G. I. Murray, M. C. Nicolson, P. H. Rooney, D. Bissett, and E. S.R. Collie-Duguid Tumor Transcriptome Reveals the Predictive and Prognostic Impact of Lysosomal Protease Inhibitors in Non-Small-Cell Lung Cancer J. Clin. Oncol., April 10, 2006; 24(11): 1729 - 1744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dolnick, Q. Wu, N. J. Angelino, L. V. Stephanie, K.-C. Chow, J. R. Sufrin, and B. J. Dolnick Enhancement of 5-Fluorouracil Sensitivity by an rTS Signaling Mimic in H630 Colon Cancer Cells Cancer Res., July 1, 2005; 65(13): 5917 - 5924. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
